Trial Profile
A study evaluating safety and efficacy of long acting factor VIII (Eloctate) for tertiary prophylaxis in pediatric and young adult patients with moderate and severe haemophilia A.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2017
Price :
$35
*
At a glance
- Drugs Efmoroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- 21 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association